SPEAKER: Sure. I mean, I think the studies that were done had a different approach to this-- that if patients got to be a very low LDL level, was the therapy continued or was it stopped? And the trials have differed in that regard. I am not concerned about any LDL value being too low.

Now, the patients who we're treating-- say your LDL is above 70, you're on a maximum tolerated statin, you're on ezetimibe, and you add a PCSK9 inhibitor, you're not going to bring your LDL value down to five. I mean, we know that what PCSK9 inhibitors do is add another 50% reduction.

So typically, those patients are going to LDL values of somewhere around 30 to 40. And I'm totally comfortable. But if they get lower than that, I have no concern, because all the data that I've seen suggests that very low LDL values do not cause major safety events like we had thought they would have years ago before we looked at this carefully.

So I'm not worried about it at all. And I rarely see people whose LDL values go down into, say, below 20. I mean, that's just not common at all.